Goldman Sachs secured its third multi-billion-euro mandate from Novartis today after the Swiss pharmaceutical giant agreed a $5.1bn (€4.3bn) acquisition of Chiron, a US vaccine maker. Goldman has advised on €10bn worth of Novartis acquisitions this year. The bank is sole adviser on the Chiron deal.

In February the bank was sole adviser to Novartis on its €4.35bn purchase of Hexal, a German pharmaceuticals group. The same month Goldman worked on Novartis' $1.7bn bid for Eon Labs of the US.